Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

NCT04862949 2025-12-12

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Completed

131 enrolled 8 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05197504 2025-09-05

HCC

Completed

166 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04920981 2024-11-07

CLINATEZO

Completed

518 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06169904 2023-12-14

B7-Family Score in Urothelial Carcinoma

Completed

215 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT03559647 2023-09-01

The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Completed

358 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03330886 2023-03-13

A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

Completed

13 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05609903 2022-11-08

Anastase

Completed

52 enrolled

Breast

Breast Neoplasms

NCT03232593 2022-08-24

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Completed

1,758 enrolled

BreastGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03790397 2022-06-03

OSIREX

Completed

169 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

SARCO-CTI

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

HCC

DELINOR

CLINATEZO

B7-Family Score in Urothelial Carcinoma

The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

Anastase

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

OSIREX